Bussiness

Europe Joins US in Approval of Trastuzumab Deruxtecan in HER2+…

Posted by December 19, 2022

Based on findings from the DESTINY-Gastric01 and -02 trials, the European Commission has approved fam-trastuzumab deruxtecan-nxki monotherapy for patients with

Read More